| Jun 16 |
Street calls of the week: Upgrade for Shopify; downgrades for AMD, Paramount
|
| Jun 14 |
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
|
| Jun 13 |
Baird starts Mereo at outperform, sees alvelestat as underappreciated
|
| Jun 12 |
Ultragenyx (RARE) Posts New Data From Bone Disease Study
|
| Jun 12 |
Mereo spikes after mid-stage data for Ultragenyx-partnered bone disorder therapy
|
| Jun 12 |
Ultragenyx, Mereo drug reduces fractures in bone disorder study
|
| Jun 12 |
Why Oracle Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
|
| Jun 11 |
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
|
| May 30 |
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
|
